These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24990825)

  • 1. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria.
    Coyle D; Cheung MC; Evans GA
    Med Decis Making; 2014 Nov; 34(8):1016-29. PubMed ID: 24990825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.
    O'Connell T; Buessing M; Johnson S; Tu L; Thomas SK; Tomazos I
    Pharmacoeconomics; 2020 Sep; 38(9):981-994. PubMed ID: 32519233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Analysis of Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria From the Perspective of the Brazilian Public Health System.
    Cruz DS; da Silva Santos M; Santos B
    Value Health Reg Issues; 2021 Dec; 26():113-125. PubMed ID: 34332185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 5. The need for transparency and efficiency in reimbursement decisions relating to drugs for rare diseases.
    Coyle DA; Cheung MC; Evans GA
    Med Decis Making; 2015 Feb; 35(2):145-7. PubMed ID: 25505026
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands.
    Quist SW; Postma AJ; Myrén KJ; de Jong LA; Postma MJ
    Eur J Health Econ; 2023 Dec; 24(9):1455-1472. PubMed ID: 36633725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
    Miyasaka N; Miura O; Kawaguchi T; Arima N; Morishita E; Usuki K; Morita Y; Nishiwaki K; Ninomiya H; Gotoh A; Imashuku S; Urabe A; Shichishima T; Nishimura J; Kanakura Y
    Int J Hematol; 2016 Jun; 103(6):703-12. PubMed ID: 26857155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.
    Cheng WY; Sarda SP; Mody-Patel N; Krishnan S; Yenikomshian M; Mahendran M; Lejeune D; Yu LH; Duh MS
    Adv Ther; 2021 Aug; 38(8):4461-4479. PubMed ID: 34275086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Höchsmann B
    Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
    Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
    PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
    Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
    N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
    van den Brand JA; Verhave JC; Adang EM; Wetzels JF
    Nephrol Dial Transplant; 2017 Jan; 32(suppl_1):i115-i122. PubMed ID: 28391343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
    Reiss UM; Schwartz J; Sakamoto KM; Puthenveetil G; Ogawa M; Bedrosian CL; Ware RE
    Pediatr Blood Cancer; 2014 Sep; 61(9):1544-50. PubMed ID: 24777716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of transparency in assessing the feasibility of modeling rare disease.
    Johnson SJ; Davis MR; Wang ST
    Med Decis Making; 2015 Feb; 35(2):143-4. PubMed ID: 25505051
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost-effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting.
    Hakimi Z; Wilson K; McAughey E; Pochopien M; Wojciechowski P; Toumi M; Knight C; Sarda SP; Patel N; Wiseman C; de Castro NP; Nazir J; Kelly RJ
    J Comp Eff Res; 2022 Sep; 11(13):969-985. PubMed ID: 35796199
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
    Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
    JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
    J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
    Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
    Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.
    Ninomiya H; Obara N; Chiba S; Usuki K; Nishiwaki K; Matsumura I; Shichishima T; Okamoto S; Nishimura JI; Ohyashiki K; Nakao S; Ando K; Kanda Y; Kawaguchi T; Nakakuma H; Harada D; Akiyama H; Kinoshita T; Ozawa K; Omine M; Kanakura Y
    Int J Hematol; 2016 Nov; 104(5):548-558. PubMed ID: 27464489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.